Regulatory Intelligence & Strategy
India & Emerging Markets Compliance
CDSCO compliance, Schedule M gap assessments, WHO-GMP certification support and India-to-export bridging for pharmaceutical manufacturers seeking to meet international regulatory standards.
Executive Overview
India is the world's largest supplier of generic medicines, with a pharmaceutical manufacturing sector that serves domestic and export markets across the globe. Indian manufacturers supply a significant proportion of the medicines used in the EU, UK and US — making their GMP compliance a matter of international supply chain integrity. Regulatory authorities including the FDA, EMA and MHRA inspect Indian manufacturing sites with growing frequency and with increasingly detailed expectations.
The revised Schedule M requirements, WHO GMP certification obligations and the specific expectations of international regulatory authorities create a complex compliance landscape for Indian manufacturers. Organisations must simultaneously meet domestic CDSCO requirements, international export market standards and the individual quality requirements of multinational pharmaceutical clients. These obligations are not always aligned, and the gaps between them are not always obvious without specialist knowledge of each framework.
Sthira Assure provides compliance consulting for Indian pharmaceutical manufacturers and for multinational organisations managing supply chains that include Indian manufacturing sites. Our team has direct knowledge of CDSCO requirements, Schedule M implementation expectations, WHO GMP inspection standards and the specific findings that FDA, EMA and MHRA inspectors consistently raise at Indian sites.
Regulatory Frameworks
- CDSCO (Drugs & Cosmetics Act)
- Schedule M (Revised 2023)
- WHO Technical Report Series
- PIC/S GMP
- FDA 21 CFR 210/211
- EU GMP Parts I & II
- MHRA GMP Requirements
Discuss India Compliance
Speak with our team about your India market and export compliance requirements.
Request a ConsultationCommon Compliance Risks
Schedule M Revised Requirements
The revised Schedule M under the Drugs and Cosmetics Act 1940 introduced significantly strengthened requirements for pharmaceutical manufacturers in India, aligning more closely with international GMP standards. Many manufacturers have not yet fully implemented the revised requirements, creating compliance gaps that affect both domestic market position and export eligibility. Regulatory assessments against current Schedule M expectations are essential before CDSCO or export authority inspections.
Export Market Compliance Gaps
Indian pharmaceutical manufacturers seeking to supply EU, UK or US markets face requirements that differ from — and in many areas exceed — domestic CDSCO standards. Organisations that have not systematically assessed the gap between their current practices and EU GMP, FDA 21 CFR or MHRA requirements risk import alerts, rejection of export applications or warning letters following international authority inspections of Indian manufacturing sites.
WHO Prequalification Readiness
WHO prequalification is essential for access to major procurement programmes, including UNICEF, GFATM and government tenders in regulated markets. WHO GMP requirements align closely with PIC/S standards and differ in specific areas from both CDSCO and FDA requirements. Manufacturers that assume WHO compliance is equivalent to domestic CDSCO compliance discover gaps during WHO inspection that create delays and require unplanned remediation.
Data Integrity in Indian Manufacturing Environments
Data integrity remains among the most frequently cited areas in FDA warning letters and EMA inspection findings involving Indian manufacturing sites. Manual data entry, inadequate audit trail configuration, shared login credentials and paper-based systems that have been digitised without adequate validation are recurring themes. Any Indian manufacturer supplying or seeking to supply regulated export markets must demonstrate robust data integrity controls as a prerequisite.
Scope of Services
Typical Deliverables
Frequently Asked Questions
What is Schedule M and why does it matter?
Schedule M of the Drugs and Cosmetics Rules 1945 sets the Good Manufacturing Practice requirements for pharmaceutical manufacturers in India. The revised Schedule M, notified in 2023, substantially updated these requirements to align more closely with international standards including WHO GMP and PIC/S GMP. Compliance with revised Schedule M is mandatory for licensed manufacturers and is increasingly the baseline that international regulatory authorities expect when inspecting Indian export sites.
What do EU inspectors focus on when auditing Indian manufacturing sites?
EU GMP inspection findings at Indian manufacturing sites consistently focus on data integrity — audit trail configuration, prevention of data manipulation, electronic record management — as well as change control rigour, CAPA effectiveness, stability programme compliance, sterile manufacturing controls (Annex 1) and the management of OOS and deviation investigations. Sites should assume data integrity and documentation practices will be scrutinised intensively.
How do you support WHO-GMP certification?
We conduct readiness assessments against WHO Technical Report Series GMP requirements, identifying gaps in quality systems, manufacturing practices, documentation, equipment qualification and process validation. We then work with the manufacturer to develop remediation plans, support implementation and prepare the site for WHO inspection. We also provide support during the inspection itself and for responding to WHO post-inspection observations.
Can you support Indian CDMOs seeking to qualify with multinational clients?
Yes. We conduct independent GxP audits of Indian CDMO and CRO facilities against the requirements of EU GMP, FDA CGMP, ICH Q10 and the specific quality standards of multinational pharmaceutical clients. Our audit reports provide the evidence base that multinational clients require to qualify Indian CDMOs in their approved supplier lists and meet their own regulatory obligations for outsourced manufacturing oversight.
Discuss India & Export Compliance
Contact our team to discuss your CDSCO, WHO-GMP or export market compliance requirements and the programme your organisation needs.